BUY Glenmark Pharmaceuticals — Prashant P. Sawant, 29 Jul 2026

byPrashant P. SawantHorizon: NA (inferred Intraday)29 Jul 2026, 8:26 am ISTvia CNBC Awaaz.

Entry₹2,196.4Inferred

Target₹2,255

Stop loss₹2,195-0.06% risk

Exit₹2,19529 Jul 2026, 9:15 am

Stop-loss hit-0.06%

Follow Prashant P. Sawant for new calls(5% target hit, 21 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 29 Jul 2026

3 supporting0 opposing

Supports the BUY call (3)

Glenmark Pharmaceuticals Inc., USA has launched Sugammadex Injection in single-dose vials, available in 200 mg/2mL and 500 mg/5mL strengths.

BSE · Company Update·28 Jul · today

1 other SEBI-registered advisor has an active intraday BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·29 Jul · today

1 advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·24 Jul · 4d ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.